BMS welcomes TGA registration of its first-in-class TYK2 inhibitor

Bristol Myers Squibb has welcomed TGA registration of SOTYKTU (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. …